Richard A. Young - Jun 1, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: Director
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Stock symbol: SYRS
Transactions as of: Jun 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/2/2023, 04:27 PM
Previous filing: May 3, 2023
Next filing: Jun 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Award	$0	+4K	+12.43%	$0.00	36.2K	Jun 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Stock Option (right to buy)	Award	$0	+6K		$0.00	6K	Jun 1, 2023	Common Stock	6K	$3.70	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The amount of securities beneficially owned following the transaction reported in this Form 4 reflects the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.
F2	The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.